Is enxidipine covered by medical insurance? How much does it cost?

Enasidenib is a targeted anticancer drug mainly used to treat patients with acute myeloid leukemia (AML) who carry isocitrate dehydrogenase2 (IDH2) mutations. AML is a cancer that affects the white blood cells in the bone marrow, often leading to bone marrow dysfunction and the proliferation of abnormal white blood cells. IDH2mutations are common in some AML patients. Such mutations can lead to abnormal metabolic pathways and promote the growth and survival of cancer cells. Ensidipine restores the normal metabolic process of cells by inhibiting the mutated IDH2 enzyme, inducing the differentiation and apoptosis of cancer cells, thereby inhibiting cancer progression.

Multiple clinical trials have verified the efficacy of ensidipine. Studies have shown that patients with IDH2-mutated AML who received ensidipine showed significant response rates, prolonged progression-free survival and improved overall survival. These results significantly improved patient outcomes. Ensidipine is usually given as an oral tablet once daily. Common side effects include nausea, vomiting, diarrhea, fatigue and loss of appetite. In addition, ensidipine may cause a serious complication called differentiation syndrome, an inflammatory response caused by rapid differentiation of cancer cells that requires prompt recognition and treatment.

As of now, Ensidipine has not been launched in mainland China, nor has it been included in China's medical insurance directory. Therefore, domestic patients cannot purchase this drug through formal channels, nor can they be reimbursed through medical insurance. To obtain ensidipine, patients need to purchase it through overseas channels. In foreign markets, there are some cheaper generic drugs, mainly from Laos and Bangladesh. The price of these generic drugs is about 2,000 yuan, and their pharmaceutical ingredients are basically the same as the original drugs, with similar efficacy and safety. The emergence of generic drugs has provided many patients with affordable treatment options.

As a targeted therapy, ensidipine has greatly changed the treatment paradigm for specific AML patients, providing an effective treatment option for those carrying IDH2 mutations. Although its scope is limited, ensidipine can provide significant therapeutic benefit to patients when the presence of the mutation is confirmed through genetic testing.